<div id="readability-page-1" class="page"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>China Traditional Chinese Medicine Holdings Co ( (HK:0570) ) has shared an update. China Traditional Chinese Medicine Holdings has scheduled a board meeting for 20 March 2026 to review and approve the consolidated final results for the year ended 31 December 2025. The board will also consider the declaration of a final dividend, potentially affecting shareholder returns and signaling management’s view on the group’s financial performance. The company disclosed the current composition of its 12-member board, comprising executive, non-executive, and independent non-executive directors, underscoring its existing governance structure. Investors will closely watch the upcoming results and any dividend decision for insight into earnings quality, cash flow strength, and the group’s capital allocation priorities. The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page. More about China Traditional Chinese Medicine Holdings Co China Traditional Chinese Medicine Holdings Co. Limited is a Hong Kong-incorporated company engaged in the traditional Chinese medicine industry. It operates through various subsidiaries, focusing on the development, production, and sale of traditional Chinese medicinal products and related healthcare services in its core markets. Average Trading Volume: 13,730,296 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$9.87B For an in-depth examination of 0570 stock, go to TipRanks’ Overview page.</div>

00570

159316

516930

China Traditional Chinese Medicine Holdings Co (HK:0570) has scheduled a board meeting for March 20, 2026, to approve its consolidated final results for the year ending December 31, 2025, and to consider declaring a final dividend. This decision may impact shareholder returns and reflect management's assessment of the company's financial performance. The board consists of 12 members, including executive and independent directors. Analysts currently rate the stock as a Hold with a price target of HK$2.00. The company focuses on traditional Chinese medicine and related healthcare services.

Tip Ranks

TRAD CHI MED

E Fund Hang Seng SCHK Innovative Drug ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal 800 Health Care ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI HK Equities Medical and Health Integration ETF

Guotai SSE STAR Brand Name Drug ETF

GF CSI All Share Health Care ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

China TCM Sets March Board Meeting to Approve 2025 Results and Consider Final Dividend